Hypoglossal Nerve Stimulator Outcomes for Patients Outside the U.S. FDA Recommendations

Objectives The hypoglossal nerve stimulator (HGNS) is currently approved for the treatment of obstructive sleep apnea (OSA) in patients with an apnea‐hypopnea index (AHI) of >15 to ≤65 events/hour, and a central apnea index (CAI) 50% and AHI 

Saved in:
Bibliographic Details
Published in:The Laryngoscope 2020-04, Vol.130 (4), p.866-872
Main Authors: Sarber, Kathleen M., Chang, Katherine W., Ishman, Stacey L., Epperson, Madison V., Dhanda Patil, Reena
Format: Article
Language:English
Subjects:
Body mass index
Food and Drug Administration
hypoglossal nerve stimulator
neurostimulation
Obstructive sleep apnea
Sleep apnea
surgery for obstructive sleep apnea
Surgical outcomes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives The hypoglossal nerve stimulator (HGNS) is currently approved for the treatment of obstructive sleep apnea (OSA) in patients with an apnea‐hypopnea index (AHI) of >15 to ≤65 events/hour, and a central apnea index (CAI) 50% and AHI 
ISSN:0023-852X
1531-4995
DOI:10.1002/lary.28175